Valuation : Sernova Biotherapeutics Inc

Market Cap 41.54M 29.9M 25.76M 24.16M 22.05M 2.86B 41.67M 287M 112M 1.44B 112M 110M 4.78B P/E 2026 *
-3.67x
P/E 2027 * -2.75x
Enterprise Value 41.54M 29.9M 25.76M 24.16M 22.05M 2.86B 41.67M 287M 112M 1.44B 112M 110M 4.78B EV / Sales 2026 *
-
EV / Sales 2027 * 8.31x
Free-Float
86.84%
Yield 2026 *
-
Yield 2027 * -
1 month-8.33%
3 months-21.43%
6 months-21.43%
Current year-15.38%
1 week 0.1
Extreme 0.105
0.12
1 month 0.1
Extreme 0.1
0.12
Current year 0.1
Extreme 0.1
0.2
1 year 0.1
Extreme 0.1
0.2
3 years 0.1
Extreme 0.1
0.91
5 years 0.1
Extreme 0.1
2.22
10 years 0.1
Extreme 0.095
2.87
Manager TitleAgeSince
Chief Executive Officer 58 12/08/2024
Director of Finance/CFO 60 11/10/2024
Investor Relations Contact - 11/10/2024
Director TitleAgeSince
Director/Board Member 60 19/04/2012
Director/Board Member - 24/04/2023
Director/Board Member - 01/09/2024
Date Insider Type Main position Quantity % Market Cap.
3/7/26 SellCompany -115,000 0.0305%
22/5/26 Option

Chairman

228,912 0.0658%
22/5/26 Option

Director

260,000 0.0748%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-40.54%-85.33% 29.97M
+1.72%-0.59%-15.95%+17.68% 124B
-0.93%-0.65%-22.84%-0.98% 12.26B
-0.90%-2.66%+86.39%+143.15% 10.72B
+0.28%-3.12%-50.49%-68.68% 4.21B
-0.42%+1.76%-16.33%+56.71% 2.73B
+1.10%-1.44%-32.80%-71.89% 1.76B
-0.45%-3.30%-19.33%-13.90% 1.63B
-5.12%-9.19%-40.28%-40.63% 1.6B
Average -0.55%-0.51%-16.91%-7.10% 17.61B
Weighted average by Cap. +1.14%-1.41%-10.95%+21.18%

Financials

2026 *2027 *
Net sales - 5M 3.6M 3.1M 2.91M 2.65M 344M 5.02M 34.5M 13.46M 174M 13.51M 13.22M 576M
Net income -12.83M -9.23M -7.96M -7.46M -6.81M -882M -12.87M -88.49M -34.53M -445M -34.66M -33.91M -1.48B -19.77M -14.23M -12.26M -11.5M -10.5M -1.36B -19.83M -136M -53.22M -687M -53.43M -52.27M -2.28B
Net Debt - -
Logo Sernova Biotherapeutics Inc
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Employees
8
Date Price Change Volume
27/08/26 CA$0.1100 0.00% 51,456
26/08/26 CA$0.1100 0.00% 4,000
25/08/26 CA$0.1100 0.00% 68,110
24/08/26 CA$0.1100 0.00% 40,202
21/08/26 CA$0.1100 0.00% 121,565
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1100CAD
Average target price
0.4500CAD
Spread / Average Target
+309.09%

Quarterly revenue - Rate of surprise